Reference,Reference: DOI,Assay,Section,Pre-vaccine Infection,Vaccine,# Shots,Months,Host,Control,Control: NT50 Cmp,Control: NT50 GeoMean,Control: NT50 GSD,Variant,Variant: Pos,Variant: Mutations,# Results,Potency: NT50 Cmp,Potency: NT50 GeoMean,Potency: NT50 GSD,Fold Reduction: Cmp,Fold Reduction: Median
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 2,None,Ad26.COV2.S,1,2-6m,Human,Wild Type (B.1),=,46.0,1.0,Lambda,75,G75V + T76I + Δ246-252 + L452Q + F490S + M869N,1,=,21.0,1.0,=,2.2
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 2,None,Ad26.COV2.S,1,2-6m,Human,Wild Type (B.1),=,98.0,1.0,Lambda,75,G75V + T76I + Δ246-252 + L452Q + F490S + M869N,1,=,20.0,1.0,=,4.9
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 2,None,Ad26.COV2.S,1,2-6m,Human,Wild Type (B.1),=,133.0,1.0,Lambda,75,G75V + T76I + Δ246-252 + L452Q + F490S + M869N,1,=,47.0,1.0,=,2.8
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 2,None,Ad26.COV2.S,1,2-6m,Human,Wild Type (B.1),=,333.0,1.0,Lambda,75,G75V + T76I + Δ246-252 + L452Q + F490S + M869N,1,=,24.0,1.0,=,13.9
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 2,None,Ad26.COV2.S,1,2-6m,Human,Wild Type (B.1),=,244.0,1.0,Lambda,75,G75V + T76I + Δ246-252 + L452Q + F490S + M869N,1,=,36.0,1.0,=,6.8
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 2,None,Ad26.COV2.S,1,2-6m,Human,Wild Type (B.1),=,268.0,1.0,Lambda,75,G75V + T76I + Δ246-252 + L452Q + F490S + M869N,1,=,59.0,1.0,=,4.5
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 2,None,Ad26.COV2.S,1,2-6m,Human,Wild Type (B.1),=,251.0,1.0,Lambda,75,G75V + T76I + Δ246-252 + L452Q + F490S + M869N,1,=,70.0,1.0,=,3.6
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 2,None,Ad26.COV2.S,1,2-6m,Human,Wild Type (B.1),=,38.0,1.0,Lambda,75,G75V + T76I + Δ246-252 + L452Q + F490S + M869N,1,=,13.0,1.0,=,2.9